Skip to main content

Table 1 Study characteristics

From: TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis

Study

Number of FTD patients

Number of ALS patients

Number of FTD and/or ALS patients

Number of controls

Males

Females

Age FTD (years)

Age ALS (years)

Age ALS-FTD (years)

Age control (years)

Pathology in controls

Screening technique

Analysis technique

Risk of bias

Hosokawa et al., 2014 [14]

N/A

13

13

7

12

8

Ā 

59

59

49

GBS

Clinical diagnosis

ELISA

Low

Noto et al., 2011 [15]

N/A

27

27

50

N/A

N/A

N/A

N/A

N/A

N/A

PD, PSP, MS, MSA, GBS, FS

El Escorial and Awaji

ELISA

Low

Kasai et al., 2009 [16]

N/A

30

30

29

19

11

N/A

65

65

69

Nonneurodegenerative/neurological patients and healthy controls

El Escorial

ELISA

Low

Feneberg et al., 2014 [17]

4

9

13

8

14

7

66

64

65

62

Nonneurodegenerative/neurological patients

El Escorial

Western blotting and mass spectrometry

Semiquantitative analysis

Suarez-Calvet et al., 2014 [20]

25

N/A

25

22

29

18

67.8

N/A

67.8

70.1

Healthy controls

FTD consensus clinical criteria + CSF biomarker profile to exclude AD.

ELISA compared to manufactured control

No blinding

Kuiperji et al., 2017 [19]

36

N/A

36

21

N/A

N/A

N/A

N/A

N/A

N/A

Healthy controls

El Escorial

ELISA

Low

Steinacker et al., 2008 [18]

24

15

27

13

24

18

68

55

63

60

Nonneurodegenerative/neurological patients

El Escorial, DSMIV, fMRI, PM lab confirmation

Immunoblot intensity against internal standard

Semiquantitative analysis and concentration compared to single FTD sample

Total

77

94

171

150

98

62

Medianā€‰=ā€‰67.8

Medianā€‰=ā€‰61.5

Medianā€‰=ā€‰65

Medianā€‰=ā€‰65.5

N/A

N/A

N/A

N/A

  1. Total sample sizes given at the bottom of the first four columns (Excluding Saurez-Calvet et al., [20]). Mean ages given at the bottom of the age columns. Where no further disambiguation was given for the ā€˜pathology in controlsā€™, ā€˜Non-neurodegenerative neurological patientsā€™ is stated. Diagnostic tools and further patient screening techniques are presented in the screening techniques column. Method of analysing CSF TDP-43 is stated in the ā€˜Analysis Techniquesā€™ column. Risks of bias uncovered through quality screening using QUADAS-2 is given in the ā€˜Risk of Biasā€™ column. QUADAS-2 findings detailed in Appendix ii NAā€‰=ā€‰Not Available. (ALS amyotrophic lateral sclerosis, FTD frontotemporal dementia, GBS Guillain-BarrĆ© syndrome, PD Parkinsonā€™s disease, PSP progressive supranuclear palsy, MS multiple sclerosis, MSA multi-system atrophy, FS functional signs, PM post-mortem)